Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Advanced Solid Tumor 3 Neoplasm Metastasis 2 Melanoma 2 Esophageal Squamous Cell Carcinoma 2 Advanced Solid Tumour 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Simpson-Golabi-Behmel syndrome 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Metastatic Solid Tumors 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Diabetes Mellitus 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Tumors 1 Advanced Malignancies 1 Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 34 Carboplatin 32 pembrolizumab 28 Pemetrexed 27 Magnetic Resonance Spectroscopy 27 Cisplatin 22 Paclitaxel 15 durvalumab 13 Gemcitabine 13 Docetaxel 12 osimertinib 11 Nivolumab 11 atezolizumab 8 Immunoglobulin G 8 Disulfides 8 Taxes 7 Etoposide 7 130-nm albumin-bound paclitaxel 7 Radiotherapy 6 Radiosurgery 6 Radiation 6 Platinum 6 Biopsy 6 X-Rays 5 Cetuximab 5 1,2-diaminocyclohexaneplatinum II citrate 5 Ramucirumab 4 Observation 4 Irinotecan 4 Interviews as Topic 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Neoplasms × tislelizumab × 30 days × Clear all

NCT07019675 2026-05-08

A Study of SKB518 in Patients With Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡